Table 1.

Underlying causes of death by treatment group (total deaths = 153)

	All causes		Cardiovascular*		Cancer		Other†
	N	% (CI)	N	% (CI)	N	% (CI)	N	% (CI)
Glimepiride	43	28.1 (21.6, 35.7)	13	30.2 (18.6, 45.1)	13	30.2 (18.6, 45.1)	17	39.5 (26.4, 54.4)
Glargine	42	27.5 (21.0, 35.0)	19	45.2 (31.2, 60.1)	12	28.6 (17.2, 43.6)	11	26.2 (15.3, 41.1)
Sitagliptin	41	26.8 (20.4, 34.3)	19	46.3 (32.1, 61.3)	9	22.0 (12.0, 36.7)	13	31.7 (19.6, 47.0)
Liraglutide	27	17.6 (12.4, 24.5)	8	29.6 (15.9, 48.5)	7	25.9 (13.2, 44.7)	12	44.4 (27.6, 62.7)

The percentages (95% CI) in the “all causes” column refer to the proportion of fatal cases in each treatment group. For the remaining columns, the percentages (95% CI) refer to the proportion of cause-specific mortality by randomized treatment.

*Cardiovascular: “cardiovascular-cause” mortality, including death from MACE (known MI or stroke or within 30 days of an MI or stroke), presumed CVD (sudden death with a history of CVD and absence of other cause), sudden death without a specific noncardiac cause, and unknown cause of death.

†Other includes other, infection, chronic liver disease, respiratory, pneumonia, accident, suicide, end-stage renal (end-stage renal death), overdose, and dementia.